Steroid added to pain injections during knee replacement surgery for knee osteoarthritis
Compares two steroid types added to pain injections in adults having knee replacement.
Key facts
- Who runs it
- Walter Reed National Military Medical Center
- Where
- Bethesda, United StatesSee the site
- Trial code
- Registry title
- Use of Corticosteroid in Intraopertive Injections in Total Knee Replacement Surgery.
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 240 people, planned
- Started
- 1 Sept 2026
- Expected to end
- 31 Aug 2027
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- PAI
- PAI + steroid
- PAI + zilretta
- Record updated
- 19 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults having a first (primary) total knee replacement at certain US military health centers. It compares a standard pain injection given during surgery, with or without a steroid added.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- People having a primary total knee replacement (TKA), for example for severe knee arthritis or injury. The surgery must be successful.
Main reasons for not taking part
- Partial knee replacement (unicompartmental knee arthroplasty)
- Repeat (revision) knee replacement
- Women who are pregnant or breastfeeding
- Allergy to ingredients of the pain injection, or a past bad reaction to the study steroids
- People with diabetes cannot be in the methylprednisolone group
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Patients within the MHS who are DEERS eligible undergoing primary TKA at Walter Reed National Military Medical Center (WRNMMC), Surgery Center of Chevy Chase or District Surgery Center
- Age 18 or older
- successful surgical intervention
Who cannot take part
- Allergic to ingredients in PAI or previous adverse reaction to steroids being used in this study
- Unicompartmental knee arthroplasty (UKA)
- Revision total knee arthroplasty (rTKA)
- Females who are pregnant or nursing
- Diabetics will be excluded from Group 2 (standard PAI + methylprednisolone)
Where in United States
- Walter Reed National Military Medical CenterBethesda, United StatesContact: John P Cody, MDTaking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to find out which type of steroid medicine, when added to a standard pain-control injection during total knee replacement surgery, works best at reducing pain, limiting opioid use, and improving recovery in adults undergoing surgery for severe knee arthritis or injury.
Read full original descriptionShow less
The main questions it aims to answer are:
Does adding a steroid to the injection improve pain control and reduce opioid use after surgery? Is the newer extended-release steroid (Zilretta) more effective and safer-especially for patients with diabetes-than the traditional steroid (methylprednisolone)?
Researchers will compare:
Standard pain-control injection alone Standard injection plus methylprednisolone Standard injection plus Zilretta to see which option provides better pain relief, less opioid use, and improved knee function.
(Patients with diabetes or prediabetes will only be in the standard injection or Zilretta groups so researchers can study whether Zilretta is safer for blood sugar control.)
Participants will:
Be randomly assigned to one of the study groups during their total knee replacement surgery Receive the assigned pain-control injection around the knee joint
Be followed after surgery to measure:
Pain levels Opioid pain medication use Knee movement (range of motion) Whether another procedure (such as manipulation under anesthesia) is needed if the knee becomes too stiff Patient-reported outcome surveys about pain and function
The 3 groups in the trial
- Standard PAIExisting treatment, for comparison
Group1 (n=80; 40 non-diabetic and 40 diabetic participants): Standard PAI: 30 mg Toradol/ketorolac (30mg/ml), 49.25ml 0.5% ropivacaine (5mg/ml), and 0.5 mg epinephrine (1mg/ml), 0.8 ml clonidine (0.1mg/ml) and 8.45 ml 0.9% sodium chloride
Treatment: PAI
- MethylprednisoloneExisting treatment, for comparison
2\. Group2 (n=40, non-diabetic): Standard PAI + 40mg methylprednisolone (n = 40)
Treatment: PAI + steroid
- ZilrettaExisting treatment, for comparison
3\. Group3 (n=80; 40 non-diabetic and 40 diabetic participants): Standard PAI + 32mg Zilretta (triamcinolone acetonide extended release injectable suspension)
Treatment: PAI + zilretta
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Adjunctive Use of Corticosteroid in Periarticular Injections in Primary Total Knee Arthroplasty
- Plain-language title
- Steroid added to pain injections during knee replacement surgery for knee osteoarthritisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 19 August 2026